Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Weill Med Col Of Cornell, New York

Columbia University Medical Center (Cumc), New York

Memorial Sloan Kettering Cancer Center, New York

Montefiore Medical Center, The Bronx

Roswell Park Cancer Institute, Buffalo

St. Agnes Hospital, Baltimore

Leo W.Jenkins Cancer Center, Greenville

Hazard Arh Regional Medical Center, Hazard

Oncology Hematology Care, Cincinnati

American Health Network, Avon

St Vincent Frontier Cancer Center, Billings

Alexian Brothers Medical Center, Elk Grove Village

The Cancer Institute At Alexian Brothers, Elk Grove Village

Northwest Oncology & Hematology, SC, Rolling Meadows

Hematology/Oncology Of The North Shore, Lake Forest

Northwest Oncology & Hematology, SC, Hoffman Estates

Healthcare Research Network III, LLC, Tinley Park

Mount Sinai Hospital, Chicago

Cancer Center Of Kansas, Wichita

Huntsman Cancer Hospital, Salt Lake City

Oregon Health & Science University, Portland

Fred Hutchinson Can Res Ctr, Seattle

Providence Regional Cancer Partnership, Everett

Local Institution - 0009, Hackensack